Clinical trial
A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
NCT00445458 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer
- Lead sponsor
- Puma Biotechnology, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 11, 2007
- Completion date
- February 7, 2018
- Enrollment
- 110 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.
advanced breast cancer, advanced malignant solid tumors, breast neoplasms